Апстракт
Background: Diabetes and its complications remain a major health challenge in Nigeria.
Aim: To evaluate the economic cost of type 2 diabetes mellitus in a secondary healthcare facility in lbadan, Nigeria.
Methods: The study was carried out in Oyo state general hospital Ibadan, Nigeria using two methods of data collection. A retrospective study design in which data were extracted from case files of diabetic patients using a pre-designed data form and secondly with an Open-ended, Affirmation, Reflective listening and Summaries (OARS) method. Data was analysed using frequencies mean and correlation statistical tools.
Results: Majority of the patients (73%) earned less than $125 per month. Hypertension was the most common (98.08%) co-morbid disorder with diabetes mellitus and the most common complication noted was neuropathy (48.10%). Metformin was the most widely prescribed oral hypoglycemic agent (90.40%). The annual cost of diabetes mellitus was $20,827.37 for the 52 patients while the average annual cost of diabetes per patient was $400.52 but higher in age group 60-69 years. There was a significant correlation (p <0.05) between age (at onset of diabetes and at registration at the healthcare facility) and total cost of drugs used.
Conclusion: The study demonstrated that type 2 diabetes mellitus and its complications imposed significant economic burden on the patients. There is need for the policy maker of health sector in the country to plan towards reducing the financial burden of diabetes on the society.
Keywords: Diabetes mellitus, cost, complication, implication, burden, medication
Résumé
Contexte: Le diabète et ses complications restent un défi majeur de santé au Nigeria.
Objectif: Pour évaluer le coût économique du diabète type 2 dans un établissement de soins de santé secondaire à Ibadan, Nigeria.
Méthodes: L’étude a été effectuée à l’hôpital général de l’État d’Oyo, Ibadan, Nigeria en utilisant deux méthodes de collecte de données. Une conception d’étude rétrospective dans laquelle les données ont été extraites des fichiers de patients diabétiques en utilisant un formulaire de données préconçus et d’autre part avec la méthode d’écoute Ouverte, Affirmation, Réflective et Résumés (OARS). Les données ont été analysées à l’aide des outils statistiques de moyennes fréquences et de corrélation.
Résultats: La majorité des patients (73%) recevait moins de $125 par mois. L’hypertension était la comorbidité la plus commune (98,08%) avec le diabète de Mellites et la complication notée la plus fréquente était la neuropathie (48,10%). Metformine était l’agent hypoglycémiant oral le plus largement prescrit (90,40 de%). Le coût annuel du diabète de Mellites était de $20,827.37 pour les 52 patients alors que le coût moyen annuel par patient du diabète était de $ 400,52 mais plus élevé dans le groupe d’âge de 60 à 69 ans. Il y avait une corrélation significative (p <0,05) entre l’âge (à l’apparition du diabète et inscription à l’établissement de santé) et le coût total des médicaments utilisés.
Conclusion: L’étude a démontré que le diabète type 2 et ses complications imposaient de grave charge économique sur les patients. Il est nécessaire que les donneurs d’ordre politique dans le secteur de santé du pays commencent à planifier en vue de réduire le fardeau financier du diabète dans la société.
Mots-clés: Diabète de Mellites, coût, complication, implication, charge, medications
Correspondence: AE Ipingbemi, Department of Clinical Pharmacy and Pharmacy Administration, University of Ibadan, Nigeria. E-mail: pharmaduke@yahoo.com
Референце
International Diabetes Federation: IDF Diabetes Atlas. 6th edition. Brussels, Belgium: International Diabetes Federation; 2013:30 [http://www.idf.org/ diabetesatlas]
Wild S, Roglic G, Green A, Sicree R and King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-1053.
Ohwovoriole AE, Kuti JA and Kabiawu SI. Casual blood glucose levels and prevalence of undiscovered diabetes mellitus in Lagos metropolis Nigerians. Diabetes Research and Clinical Practice 1988; 7: 153-158.
Akinkugbe OO. The Non-communicable Diseases in Nigeria-Report of a National Survey. Ibadan: Intec Printers Limited.1997
Owoaje EE, Rotimi CN, Kaufman JS, Tracy J and Cooper RS. Prevalence of adult diabetes in Ibadan, Nigeria. E Afr Med J 1997; 74: 299- 302
Nyenwe EA, Odia OJ, Ihekwaba AE, Ojule A and Babatunde S. Type 2 diabetes in adult Nigerians: a study of its prevalence and risk factors in Port Harcourt, Nigeria. Diabetes Research and Clinical Practice 2003; 62: 177-185.
Bakari AG and Onyemelukwe GC. Glucose intolerance among apparently health Hausa-Fulani Northerner Nigerians. Ann Afr Med. 2004; 3:32 – 34.
Nwafor A and Owhoji A. Prevalence of diabetes mellitus among Nigerians in Port Harcourt correlates with socio-economic status. Journal of Applied science and Environmental Management 2001; 1:75-77.
Omolase CO, Adekanle O, Owoeye JFA and Omolase BO. Diabetes retinopathy in a Nigerian community. Singapore Medical Journal. 2010; 51: 56-59.
Hogan P, Dall, T and Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26:917-932.
Zhang P, Engelgau MM, Norris SL, Gregg ED and Venkat Narayan K. Application of economic analysis to diabetes and diabetes care. Ann Intern Med 2004; 140:972-977.
American Diabetes Association (ADA). Economic Costs of Diabetes in the U.S.in 2012. Diabetes Care. 2013, 36:1033–1046.
Solli O, Jenssen T and Kristiansen SI. Diabetes: cost of illness in Norway. BMC Endocrine Disorders. 2010; 10:1-8.
González JC, Walker JH and Einarson TR. Cost-of-illness study of type 2 diabetes mellitus in Colombia. Rev Panam Salud Publica 2009; 26: 55–63.
Clarke MP, Glasziou P, Patel A, et al. Event rates, hospital utilization and costs associated with major complications of diabetes: A multicountry comparative analysis. Plos Medicine 2010; 7: 1-10.
Palmer AJ, Roze Stéphane, Valentine W J.et al. The CORE Diabetes model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion 2004; 20: 5-26.
Suleiman AI, Fadeke OF and Okunbanjo OO. Pharmacoeconomic evaluation of Anti-diabetes therapy in a Nigeria tertiary health institution. Ann Afr Med 2006; 5: 132-137.
Ipingbemi AE, Erhun WO and Awogbemi JK. Evaluation of the management and treatment outcome of diabetes mellitus in a secondary healthcare Facility in southwest Nigeria. West African Journal of Pharmacy 2014; 25 (2):88-97.
Young M. Behavioural Change and Motivational Interviewing in the patients with diabetes. Journal of Endocrinology, Metabolism and Diabetes of South Africa (JEMDSA) 2010;15: 45-47.
Kishore SG, Kuriachan MA and Subash P. Pharmacoeconomics: Cost of Illness Studies. Hygeia, 2009;1(1): 46-49.
Javanbakht M, Baradaran HR, Mashayekhi A, et al. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS One 2011; 6.10:26864.
Fezeu L, Fointama E, Ngufor G, Mbeh, G and Mbanya JC. Diabetes awareness in general population in Cameroon. Diabetes Research and Clinical Practice 2010 ;90: 312-318.
Al-Maskari F, Mohammed El-Sadiq and Nagelkarke N. Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates. BioMed Centra Public Health. 2010;10:679. http://www.biomedcentral.com/1471-2458/10/679
Enwere OO, Salako BL and Falade CO. Prescription and cost consideration at a diabetes clinic in Ibadan, Nigeria: A report. Ann of Ibadan Postgraduate Med. 2006;4: 35-39.
Trogdon JG and Hylands T. Nationally Representative Medical Costs of Diabetes by Time Series Diagnosis. Diabetes Care 2008; 31: 2307-2311.
Nigeria Bureau of Statistic. Social Statistic in 2009. Abuja: NBS.
Unachukwu C.N, Uchenna D.I and Young E. Mortality Among Diabetes In-patients in Port-Harcourt, Nigeria. African Journal of Endocrinology and Metabolism, 2008;7. 1:1-4.
www.population.gov.ng/index.php/2013-nigeria-demographic-and-health-survay.
Tharkar S, Devarajan A, Kumpatla S and Viswanatha V. The socio-economics of diabetes from a developing countries: A population based cost of illness study. Diabetes Research and Clinical Practice 2010; 89: 334-340.
Esposito K, Maioriino MI, Ceriello A, and Giugliano D. Prevention and control of type 2 diabetes by Mediterranean diet: a systematic review. Diabetes Research and Clinical Practice 2010; 89: 97-102.
Harati H, Hadaegh F, Momenan, AA, et al. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle Eastern community. American Journal of Preventive Medicine. 2010; 38: 628-636.